Imatinib (Gleevec), a well-known inhibitor of the oncogenic Bcr-abl fusion protein responsible for chronic myelogenous leukemia (CML), has been used to target PDGFR in gastrointestinal stromal tumors KIT positive. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.